Sign In
Buy GLP
$43.19
-2.42 (-5.31%)
At Close: Jun 16, 2026
Why People are Drinking Less & GLP-1 Drug Impact on Alcohol Consumption
04:30pm, Monday, 15'th Jun 2026
Marten Lodewijks, managing director and president of IWSR, breaks down what's behind the decline in global alcohol consumption. He discusses how emerging markets are impacting overall consumption tren
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
08:15am, Sunday, 14'th Jun 2026
Sales of Eli Lilly's GLP-1 drugs are growing very quickly. Eli Lilly continues to innovate in the competitive GLP-1 space.
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
11:03am, Thursday, 11'th Jun 2026
Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults living with obesity and overweight versus placebo in addition to diet and exercise Semagluti
The GLP-1 stock nobody is pricing in isn't a drugmaker
09:30am, Thursday, 11'th Jun 2026
Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults, are now on GLP-1s, and the
Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases
06:03am, Thursday, 11'th Jun 2026
Some employers are planning to drop coverage of GLP-1 drugs for weight loss next year as more people take the medications, counteracting some savings from lower prices for Novo Nordisk's Wegovy and El
2 Highly Ranked Stocks to Consider After May's Hot CPI Report: DOW, GLP
03:21pm, Wednesday, 10'th Jun 2026
With inflation pressures resurfacing and commodity markets reacting to geopolitical developments, Dow Inc. and Global Partners may be well positioned to navigate the current environment.
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
01:01pm, Wednesday, 10'th Jun 2026
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before
02:42pm, Tuesday, 09'th Jun 2026
At the American Diabetes Association's 2026 Scientific Sessions, CNBC's Angelica Peebles sat down with Novo Nordisk CEO Mike Doustdar to discuss the launch of the Wegovy pill and how it became the bes
Gen Z and GLP-1 drugs to power Gym Group's growth, says analyst
11:42am, Tuesday, 09'th Jun 2026
The Gym Group PLC (LSE:GYM) remains one of Deutsche Bank's preferred stocks in the leisure sector, with the broker arguing that powerful demographic and health trends continue to support long-term gro
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.
09:25am, Tuesday, 09'th Jun 2026
Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ Kelowna, British Columbia - June 9 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NA
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
09:25am, Tuesday, 09'th Jun 2026
Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lex
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
09:20am, Tuesday, 09'th Jun 2026
More employers and health plans are balking at paying for costly GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and the treatment of obesity, according to a new report.
Promino Launches Muscle Health Research Initiative Targeting GLP-1 Weight Management Market
06:00am, Tuesday, 09'th Jun 2026
Study designed to evaluate Rejuvenate Muscle Health(TM) among GLP-1 users while generating proprietary human evidence supporting Promino's muscle health platform Burlington, Ontario--(Newsfile Corp. -
Use of GLP-1 drugs early in pregnancy should not cause alarm
05:05pm, Monday, 08'th Jun 2026
Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is not a cause for alarm, a large new data analysis suggests.
In ACHIEVE-3, Foundayo 17.2 mg drove 57.1% greater relative reduction in A1C and 73.6% greater relative weight loss compared to oral semaglutide 14 mg In ACHIEVE-2 and ACHIEVE-5, Foundayo deliver
